O García-Bosch1, E Ricart, J Panés. 1. Department of Gastroenterology, Hospital Clínic de Barcelona, CiBERehd, Spain.
Abstract
BACKGROUND: Drugs available for the treatment of inflammatory bowel disease fail to induce and maintain remission in a significant number of patients. AIM: To assess the value of stem cell therapies for treatment of inflammatory bowel disease based on published studies. METHODS: Publications were identified through a MEDLINE search using the Medical Subject Heading terms: inflammatory bowel diseases, or Crohn's disease, or ulcerative colitis, and stem cell, or stromal cell or transplant. RESULTS: Haematopoietic stem cell therapy as a primary treatment for inflammatory bowel disease was originally supported by animal experiments, and by remissions in patients undergoing transplant for haematological disorders. Later, transplantation specifically performed for patients with refractory Crohn's disease showed long-lasting clinical remission and healing of inflammatory intestinal lesions. Use of autologous nonmyeloablative regimens and concentration of the procedures in centres with large experience are key in reducing treatment-related mortality. Initial trials of mesenchymal stem cell therapy with local injection in Crohn's perianal fistulas had positive results. CONCLUSIONS: Autologous haematopoietic stem cell transplant changes the natural course of Crohn's disease, and may be a therapeutic option in patients with refractory disease if surgery is not feasible due to disease location or extension.
BACKGROUND: Drugs available for the treatment of inflammatory bowel disease fail to induce and maintain remission in a significant number of patients. AIM: To assess the value of stem cell therapies for treatment of inflammatory bowel disease based on published studies. METHODS: Publications were identified through a MEDLINE search using the Medical Subject Heading terms: inflammatory bowel diseases, or Crohn's disease, or ulcerative colitis, and stem cell, or stromal cell or transplant. RESULTS: Haematopoietic stem cell therapy as a primary treatment for inflammatory bowel disease was originally supported by animal experiments, and by remissions in patients undergoing transplant for haematological disorders. Later, transplantation specifically performed for patients with refractory Crohn's disease showed long-lasting clinical remission and healing of inflammatory intestinal lesions. Use of autologous nonmyeloablative regimens and concentration of the procedures in centres with large experience are key in reducing treatment-related mortality. Initial trials of mesenchymal stem cell therapy with local injection in Crohn's perianal fistulas had positive results. CONCLUSIONS: Autologous haematopoietic stem cell transplant changes the natural course of Crohn's disease, and may be a therapeutic option in patients with refractory disease if surgery is not feasible due to disease location or extension.
Authors: Lloyd Mayer; William M Pandak; Gil Y Melmed; Stephen B Hanauer; Kristine Johnson; Denise Payne; Herbert Faleck; Robert J Hariri; Steven A Fischkoff Journal: Inflamm Bowel Dis Date: 2013 Mar-Apr Impact factor: 5.325
Authors: María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores Journal: World J Gastroenterol Date: 2014-02-07 Impact factor: 5.742
Authors: Maneesh Dave; Kathan Mehta; Jay Luther; Anushka Baruah; Allan B Dietz; William A Faubion Journal: Inflamm Bowel Dis Date: 2015-11 Impact factor: 5.325
Authors: Antara Banerjee; Debora Bizzaro; Patrizia Burra; Rosa Di Liddo; Surajit Pathak; Diletta Arcidiacono; Andrea Cappon; Patrizio Bo; Maria Teresa Conconi; Marika Crescenzi; Claudia Maria Assunta Pinna; Pier Paolo Parnigotto; Malcolm R Alison; Giacomo Carlo Sturniolo; Renata D'Incà; Francesco Paolo Russo Journal: Stem Cell Res Ther Date: 2015-04-16 Impact factor: 6.832